214759-73-6

Basic information

• Product Name: (4-PIPERIDINOPHENYL)METHYLAMINE
• Synonyms: AKOS B033618;(4-PIPERIDINOPHENYL)METHYLAMINE;4-PIPERIDINOBENZYLAMINE;1-(4-PIPERIDIN-1YLPHENYL)METHANAMINE;4-(Piperidin-1yl)benzylamine;(4-Piperidin-1ylphenyl)methylamine;4-(Piperidin-1yl)benzylamine, 1-[4-(Aminomethyl)phenyl]piperidine
• CAS NO: 214759-73-6
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Mol File: 214759-73-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 342.8& #176;C at 760 mmHg
• Flash Point: 141.9 °C
• Appearance: /
• Density: 1.047 g/cm³
• Vapor Pressure: 7.35E-05mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: (4-PIPERIDINOPHENYL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-PIPERIDINOPHENYL)METHYLAMINE(214759-73-6)
• EPA Substance Registry System: (4-PIPERIDINOPHENYL)METHYLAMINE(214759-73-6)

Safety Data

• Hazard Codes: C,Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 214759-73-6(Hazardous Substances Data)

Usage

General Description

(4-Piperidinophenyl)methylamine is a chemical compound with the molecular formula C12H18N2. It is a secondary amine, which means it has two carbon atoms bonded to the nitrogen atom. (4-PIPERIDINOPHENYL)METHYLAMINE is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. It has a piperidine ring, which gives it a unique cyclic structure. The compound is known for its role as a building block in the production of various drugs, including antidepressants, antipsychotics, and other therapeutic agents. It is also used as a precursor in the preparation of heterocyclic compounds and can be employed in research and development activities in the pharmaceutical industry. Additionally, (4-Piperidinophenyl)methylamine has potential applications in the field of organic chemistry for the synthesis of diverse chemical substances.

InChI:InChI=1/C12H18N2/c13-10-11-4-6-12(7-5-11)14-8-2-1-3-9-14/h4-7H,1-3,8-10,13H2

Upstream product

• 623-03-0 4-Cyanochlorobenzene 
• 110-89-4 piperidine 
• 1194-02-1 4-fluorobenzonitrile 

Downstream Products

• 581812-83-1 1-[4-(isocyanatomethyl)phenyl]piperidine 
• 1338064-53-1 1-(4-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1334717-28-0 7-chloro-2-ethyl-N-(4-(piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1227946-41-9 3-[5,6-bis(methyloxy)-2-pyridinyl]-2,4-dioxo-N-{[4-(1-piperidinyl)phenyl]methyl}-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine-6-carboxamide 
• 581811-20-3 N-(3-methyl-5-isoquinolinyl)-N'-[4-(1-piperidinyl)benzyl]urea 
• 581811-12-3 N-(3-amino-5-isoquinolinyl)-N'-[4-(1-piperidinyl)benzyl]urea 
• 581812-64-8 2,2,2-trichloro-N-(isoquinolin-5-yl)acetamide 
• 389601-48-3 N-(4-piperidin-1-yl-phenylmethyl)-3-(4'-trifluoromethyl-biphenyl-2-carbonylamino)-benzoic acid amide 
• 486435-41-0 N-[4-(piperidino)-phenylmethyl)-4-(4'-trifluoromethyl-biphenyl-2-carbonylamino)-1-methyl-pyrrole-2-carboxylic acid amide 
• 486434-74-6 N-[4-(piperidino)-phenylmethyl]-4-(4'-trifluoromethyl-biphenyl-2-carbonylamino)-1-methyl-imidazol-2-carboxylic acid amide 

Relevant articles and documents

Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents

A series of benzamide scaffolds were designed and synthesized by the thiazinone ring opening of PBTZ169, and N-benzyl 3,5-dinitrobenzamides were finally identified as anti-TB agents in this work. 3,5-Dinitrobenzamides D5, 6, 7, and 12 exhibit excellent in vitro activity against the drug susceptive Mycobacterium tuberculosis H37Rv strain (MIC: 0.0625 μg/mL) and two clinically isolated multidrug-resistant strains (MIC 0.016-0.125 μg/mL). Compound D6 displays acceptable safety and better pharmacokinetic profiles than PBTZ169, suggesting its promising potential to be a lead compound for future antitubercular drug discovery.

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent

A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active